GeneDx is trading 4.8% down at $75.83 after no clear company-specific catalyst emerged in the latest overnight coverage.
- Recent developments—the August 11 online exome-testing launch and August 3 earnings—predate this move and do not directly explain today’s decline.
- Biotech is broadly stronger in pre-market, while major U.S. indexes are nearly flat to modestly lower, leaving the immediate driver uncertain.